L444P KI mice were generated using a loxP replacement vector, resulting in the insertion of a point mutation of leucine to proline (L444P) in exon 10 of the Gba1 gene (Ginns et al., 2014). These Gba1 ...

“We have a positive trial,” announced Laura Baker of Wake Forest University, North Carolina, drawing cheers during her plenary at the 2025 Alzheimer’s Association International Conference (AAIC) in ...

Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...

Identifying genes that control protein levels could provide insight into disease development and progression. However, genetic analyses such as genome-wide associated studies identify regions ...

While anti-tau antibodies are beginning to look promising (see previous story), small molecules that modify tau proteins haven’t yet fared well in clinical trials. At the 16th Clinical Trials on ...

A top researcher’s fall from grace sends shock waves through the scientific community. Such is the case with neuropathologist Eliezer Masliah, who stands accused of image falsification spanning 26 ...

For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold. Now, scientists argue that people with two APOE4 alleles ...

In Phase 3, HMTM failed to meet co-primary endpoints. Subgroup analysis of an open-label extension suggests benefit in people with MCI. In that subgroup, half as many people transitioned to AD. HMTM ...

Biogen has thrown in the towel on its controversial anti-amyloid antibody aducanumab. The company announced January 31 that it would stop all development of the drug, and halt the post-market, ...

Part 1 of 2. Click here for Part 2. As Alzheimer’s clinicians across the U.S. started offering a disease-modifying treatment to their patients, uptake at first was slow but is now speeding up. Six ...